Showing the English original — no translation yet for this language.

个性化策略

GLP-1 First Month: What to Expect on Ozempic & Wegovy (2026)

撰写 HAVIT Editorial Team审核 HAVIT Medical Advisory · Editorial Medical Review Board

Updated 2026-07-05· 5 min read

本文仅供一般信息参考，不能替代专业医疗建议、诊断或治疗。如有任何健康相关问题，请务必咨询合格的医疗专业人员。

Quick answer

In your first month on a GLP-1, you start at the lowest dose — semaglutide 0.25 mg (Ozempic/Wegovy) or tirzepatide 2.5 mg (Mounjaro/Zepbound) — for four weeks. Expect mild early nausea, a fading appetite, and small, gradual weight loss. The starter dose is for adjustment, not results.

The first four weeks on a GLP-1 rarely look the way people imagine.

The starting dose of semaglutide — the active ingredient in Ozempic and Wegovy — is 0.25 mg once weekly, and per the FDA-approved Wegovy label this dose is below the therapeutic range: its only job is to let your body adjust to the drug with as little nausea as possible.

The same is true of tirzepatide (Mounjaro, Zepbound), which starts at 2.5 mg for four weeks per the Zepbound label.

So if the scale barely moves in month one, that is normal and expected — not a sign the medication isn't working.

Below is a realistic, week-by-week picture, followed by exactly what to track so your first clinic conversation is grounded in your own data.

GLP-1 first month, week by week (at a glance)

This table is a general timeline for the standard 0.25 mg semaglutide starter month. Individual experience varies widely; tirzepatide (2.5 mg start) follows a similar arc.

(Doses reflect the FDA Wegovy/Ozempic labels. Your prescriber decides whether and when to step up.)

Week 1: the starter dose and the first injection

Your first 0.25 mg dose introduces the drug slowly. Most people feel little on day one.

The most common early effect is mild nausea, which per the FDA labels tends to appear in the first one to three days after a dose and then eases.

Some people notice nothing at all in week one — also normal.

Two practical habits pay off immediately: choose a consistent injection day (semaglutide is once weekly, and a long ~1-week half-life means levels build gradually), and start a simple log from day one so you can see your own pattern rather than guessing.

Week 2: your body adjusts

By the second dose, many people report that early nausea is milder and more predictable.

This is also when some begin to notice the effect that GLP-1 users describe most vividly: the quieting of "food noise" — the constant background pull toward snacking.

Mechanistically, GLP-1 drugs slow gastric emptying and act on appetite centers, so you feel full sooner and stay full longer.

Lean into it: eat smaller, more frequent, lower-fat meals, stop at the first sign of fullness, and prioritize protein to protect muscle as weight starts to come off.

Week 3: appetite suppression becomes obvious

For most people, week three is when reduced appetite is clearly there — meals feel smaller, and forgetting to snack becomes normal.

Because you may also feel less thirsty, under-drinking is a real risk; sip water through the day, especially if you have any nausea or loose stools.

Keep logging side effects and their timing relative to your dose day.

Week 4: small early loss, and the first dose decision

By the end of the starter month, many people have lost a few pounds (roughly 1–3% of body weight) — a modest, gradual change, not a dramatic one.

That is exactly what the trials predict: the big results in STEP-1 (mean 14.9% weight loss with semaglutide 2.4 mg) accrued over 68 weeks at the full dose, not in month one.

Per the label schedule, week 4 is when semaglutide typically steps up from 0.25 mg to 0.5 mg (tirzepatide from 2.5 mg to 5 mg) — but only under your prescriber's direction.

Bring your log. If side effects were rough, your clinician may hold you at the current dose longer; that is a normal, common decision. Never adjust your own dose.

What to track in your first month (a HowTo)

Structured tracking turns a vague "I think it's working" into evidence you and your clinician can act on. Do these, in order:

Log your injection day and dose every week — the anchor for everything else.
Weigh weekly, not daily. Daily weight swings are mostly water and noise; a weekly trend is the real signal.
Record side effects and their timing relative to your dose (e.g., "nausea, day 2, mild").
Track meals and protein — aim to eat protein first and note portion sizes shrinking.
Log hydration, especially on days with any nausea, vomiting, or diarrhea.
Note energy, sleep, and "food noise" — non-scale wins that matter early.
Flag red-flag symptoms immediately (see below) — don't "wait it out."
Review the whole log before your next appointment so dose decisions use your real data.

Keeping this by hand is tedious, which is why a companion like the Havit app is built to make it effortless — log doses, meals, weight, and how you feel each day, and watch your own first-month pattern emerge. (It's a tracking companion, not a medical device — always defer to your clinician.)

Red flags in month one — when to call your clinician

Most first-month symptoms are mild and temporary, but per the FDA labels some need prompt attention: severe, persistent abdominal pain (possible pancreatitis — stop and seek care), upper-right abdominal pain with fever or jaundice (gallbladder), vomiting or diarrhea you can't keep fluids down through (dehydration risk), and any serious allergic reaction. For the full list and what each may mean, see our GLP-1 side effects guide.

Why HAVIT — Medication + Behavior Change, in One App

GLP-1 medications can meaningfully reduce weight — but the number on the scale is only part of the story.

Roughly 20–40% of the weight lost on GLP-1 therapy can come from lean (muscle) tissue rather than fat (Neeland et al., Diabetes, Obesity and Metabolism, 2024), and results tend to fade once the medication stops unless new habits take their place.

That's why leading guidance treats medication as one part of care, not the whole: the U.S. Preventive Services Task Force recommends that adults with obesity be offered intensive, multicomponent behavioral interventions (USPSTF, Grade B).

HAVIT is built for exactly this moment — one app that unites medication tracking, body composition, nutrition and protein, daily habit-building, and an AI coach that adapts to you.

Across our own 1,090 GLP-1 users, the most consistent trackers built the strongest habits (see the GLP-1 habit report).

Manage the medicine and the muscle — together. Start with HAVIT →

GLP-1 first month, week by week (at a glance)

Week	Typical dose (semaglutide)	What many people notice	What to focus on
Week 1	0.25 mg (first injection)	First dose; possible mild nausea 1–3 days after; appetite may start to dip	Pick a fixed weekly injection day; start logging
Week 2	0.25 mg	Nausea often mild and settling; "food noise" may quiet	Smaller portions, hydrate, protein first
Week 3	0.25 mg	Appetite suppression more noticeable; fuller sooner	Track meals and any side-effect timing
Week 4	0.25 mg → prep for 0.5 mg	Small early loss (often a few pounds / ~1–3%); reduced appetite settled	Weigh weekly; review with your prescriber before the increase

FAQ

How much weight will I lose in the first month on a GLP-1?

Usually a modest amount — often a few pounds, roughly 1–3% of body weight. The starter dose (semaglutide 0.25 mg) is below the therapeutic range and is meant for adjustment, so large first-month losses are neither expected nor the goal.

Is it normal to lose almost no weight the first month?

Yes. Per the FDA Wegovy label, the 0.25 mg starting dose isn't expected to drive significant weight loss on its own. Meaningful results build over months as the dose increases — STEP-1's 14.9% average accrued over 68 weeks.

When do GLP-1 side effects start and how long do they last?

Nausea most often appears in the first 1–3 days after a dose and eases within about 2–4 weeks as your body adjusts. Symptoms cluster around each dose increase, which is why titration is slow.

When does appetite suppression kick in?

Many people notice reduced appetite and quieter "food noise" within the first 1–2 weeks, becoming clearer by weeks 3–4. It varies — some feel it on the first dose, others after the first step-up.

What is the starting dose of Ozempic and Wegovy?

Both are semaglutide and start at 0.25 mg once weekly for four weeks per their FDA labels, then step up on a schedule your prescriber controls (Wegovy: 0.25→0.5→1.0→1.7→2.4 mg).

Does the first month differ on Mounjaro or Zepbound?

The arc is similar, but tirzepatide starts at 2.5 mg once weekly for four weeks (not 0.25 mg). Early GI effects and appetite changes follow the same pattern; the starter dose is likewise for adjustment.

What should I eat in the first month?

Smaller, lower-fat meals, protein first, and plenty of fluids — and stop at the first sign of fullness. Greasy, fried, and very sweet foods tend to worsen nausea. See our GLP-1 meal plan for a structured week.

Should I weigh myself every day?

No — weigh weekly. Daily numbers are mostly water fluctuation and can be discouraging in month one. A weekly trend is the reliable signal, and it's what your clinician will want to see.

Havit 是什么？

Havit 是一款在减重同时保住肌肉的 AI 健康伙伴。

和只计算热量的追踪器不同，Havit 把 AI 身体成分估算与饮食、水分、睡眠、步数、生理周期、情绪、GLP-1 用药记录整合成同一套每日流程，因此进度看的是身体成分，而不只是体重秤上的数字。每日任务把已验证的行为改变技巧拆成小而可重复的行动，并融入韩国代表性代谢诊所 Juvis Diet 出身专家的经验。

在 Havit 自行分析的 1,090 位 GLP-1 使用者数据中，持续记录的人比一般用户建立了更稳固的习惯。阅读 GLP-1 习惯报告

无论是否使用 GLP-1 药物都可以使用 Havit。这是一款健康类应用，不是医疗器械；身体成分结果为估算值。

Continue in the App

Personalized wellness with your own data

References

FDA — WEGOVY (semaglutide) Prescribing Information (label). accessdata.fda.gov
FDA — OZEMPIC (semaglutide) Prescribing Information (label). accessdata.fda.gov
FDA — ZEPBOUND (tirzepatide) Prescribing Information (label). accessdata.fda.gov
Novo Nordisk — Wegovy Dosing Schedule (0.25→2.4 mg). novomedlink.com
Wilding JPH, et al. — Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). NEJM 2021. nejm.org
Mayo Clinic — Tirzepatide (subcutaneous route): description, side effects, dosing. mayoclinic.org
All medical claims above were verified against the cited FDA labels, manufacturer dosing materials, and NEJM trial as of July 2026. Labels are updated periodically — confirm current details with your clinician and the official prescribing information.*